Search clinical trials for: Mantle cell Lymphoma

Total 51977 results

Henan Cancer Hospital

Not yet recruiting

This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma

Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell
InnoCare Pharma Inc.

Not yet recruiting

A Global Phase 3 Study of Orelabrutinib+BR vs.BR in Pts With TN MCL

Mantle Cell Lymphoma
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Not yet recruiting

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Fudan University

Recruiting

A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma | Maintenance Therapy

China
Roswell Park Cancer Institute

Recruiting

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell... and other conditions

United States
Paolo Corradini
Annalisa Chiappella; Cristiana Carniti; Anna Dodero

Recruiting

Italian Observational Study on CAR-T Therapy for Lymphoma (CART-SIE)

Follicular Lymphoma | Mantle Cell Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Diffuse Low Grade B-Cell Lymphoma

Italy
Stanford University
The Leukemia and Lymphoma Society

Recruiting

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Follicular Lymphoma | Burkitt Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Hairy Cell Leukemia

United States
Dalian Medical University

Not yet recruiting

Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.

Mantle Cell Lymphoma

China
Narendranath Epperla

Not yet recruiting

Pemigatinib for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma or Marginal Zone Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory Mantle Cell Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid... and other conditions

United States
Sana Biotechnology

Recruiting

Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) (VIVID)

Non Hodgkin's Lymphoma | Large B-cell Lymphoma

United States
Shanxi Province Cancer Hospital

Not yet recruiting

A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients (Z+RCHOP/RDHAP)

Mantle Cell Lymphoma

China
Atara Biotherapeutics

Recruiting

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

High-grade B-cell Lymphoma | MCL | Diffuse Large B-cell Lymphoma (DLBCL) | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | DLBCL/High-grade B-cell Lymphoma With MYC and BCL2 Rearrangements | Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma | LBCL With IRF4 Rearrangement | High-grade B-cell... and other conditions

United States
C. Babis Andreadis
Eli Lilly and Company; Genentech, Inc.; Adaptive Biotechnologies

Not yet recruiting

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Kite, A Gilead Company

Recruiting

Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (JKART-1)

Relapsed/Refractory Mantle Cell Lymphoma | Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Japan
British Columbia Cancer Agency

Not yet recruiting

Preliminary Assessment of [18F]BL40 in PET/CT Scans

Multiple Myeloma | Waldenström Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma

Canada
British Columbia Cancer Agency

Not yet recruiting

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

B-cell Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-Cell Leukemia | B-cell Acute Lymphoblastic Leukemia | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | High-grade B-cell Lymphoma

Canada
Mayo Clinic

Not yet recruiting

Nasal Iodine Swab Versus Oral Antibiotic to Prevent Surgical Site Infection After Undergoing Mohs Micrographic Surgery

Skin Cancer | Skin Cancer Face | Malignant Cutaneous Adnexal Neoplasm

United States
Mayo Clinic

Recruiting

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Recruiting

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

Mantle Cell Lymphoma | MCL

United States
Mayo Clinic

Recruiting

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Hematopoietic and Lymphoid System Neoplasm

United States
Ruijin Hospital

Recruiting

A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma

Lymphoma, Mantle-Cell

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Mantle Cell Lymphoma

China
Hoffmann-La Roche

Recruiting

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma (GLOBRYTE)

Lymphoma

Korea, Republic of, United States, Spain, France, Brazil, China, Canada, Australia, Sweden, Taiwan, Italy, United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Power Life Sciences Inc.

Not yet recruiting

Patient Perspectives in Mantle Cell Lymphoma Clinical Research

Mantle Cell Lymphoma

United States
iOMEDICO AG

Recruiting

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms (RUBIN)

Chronic Lymphocytic Leukemia (CLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Marginal Zone Lymphoma (MZL) | Waldenström's Macroglobulinemia (WM)

Germany
Cancer Research UK
Aleta BioTherapeutics

Recruiting

A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies

Lymphoma, Follicular | Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell

United Kingdom
Alvaro Alencar, MD
Incyte Corporation; BeiGene; MorphoSys AG

Recruiting

Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma (ZANU-TAFA)

Mantle Cell Lymphoma

United States
Marcela V. Maus, M.D.,Ph.D.

Recruiting

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin Lymphoma

United States
OncoNano Medicine, Inc.

Recruiting

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. (ON-5001)

Lymphoma, Non-Hodgkin | Follicular Lymphoma | Carcinoma in Situ | Mantle Cell Lymphoma | Metastatic Cancer | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Cervix Cancer | Diffuse Large B Cell Lymphoma | Head and Neck Squamous Cell Carcinoma | Tumor, Solid | Tumor Recurrence | Uveal Melanoma, Recurrent

United States
Poseida Therapeutics, Inc.
Roche-Genentech

Recruiting

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL)

United States
Massachusetts General Hospital
Varian Medical Systems

Recruiting

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

Lymphoma, B-Cell | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Lymphoma | High-grade B-cell Lymphoma | Relapsed Cancer | Mediastinal Large B-cell Lymphoma

United States
Zhejiang Cancer Hospital

Recruiting

ZR2 Sequential Immunochemotherapy for Newly Treated MCL

Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma

China
Medical College of Wisconsin

Not yet recruiting

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Follicular Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma
InnoCare Pharma Inc.
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Evaluating Different Doses of Orelabrutinib in MCL

Mantle Cell Lymphoma

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
AstraZeneca

Recruiting

A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)

Mantle Cell Lymphoma (MCL)

Canada, Poland, United Kingdom, United States, Brazil, Spain, Australia
Weill Medical College of Cornell University
Epizyme, Inc.; American Society of Clinical Oncology; Applebaum Foundation

Recruiting

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-Cell Lymphoma

United States
Fred Hutchinson Cancer Center
Faron Pharmaceuticals Ltd

Not yet recruiting

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Mantle Cell Lymphoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (V-MIND)

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
University of Milano Bicocca

Recruiting

"Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity.

Mantle-cell Lymphoma | B Cell Chronic Lymphocytic Leukemia

Italy
Joshua Sasine, MD, PhD

Recruiting

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Multiple Myeloma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Hematologic Malignancy | Large B-cell Lymphoma

United States
Sana Biotechnology

Recruiting

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States, Australia
Medical University of Vienna

Recruiting

Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

Mantle-cell Lymphoma

Austria
Peter MacCallum Cancer Centre, Australia

Recruiting

Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma Refractory

Australia
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

Mantle Cell Lymphoma | Blastoid Variant Mantle Cell Lymphoma | Pleomorphic Variant Mantle Cell Lymphoma

United States
Australasian Leukaemia and Lymphoma Group

Recruiting

A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. (GOlDiLOX)

Mantle Cell Lymphoma | Mantle Cell Lymphoma Refractory

Australia
Memorial Sloan Kettering Cancer Center
Incyte Corporation

Recruiting

A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma

Mantle Cell Lymphoma | MCL

United States
Accutar Biotechnology Inc

Recruiting

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Relapsed/Refractory B-cell Malignancies

United States
AbbVie

Recruiting

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Hematologic Cancer

United States, Israel, Japan

Search clinical trials for: Mantle cell Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations